Abstract
The results of the JAVELIN Bladder 100 (JB100) trial showed that treatment with avelumab + BSC as 1L maintenance treatment led to significant gains in overall and progression-free survival vs BSC alone. A budget impact model was developed to estimate the net cost of reimbursing avelumab for treating patients in Taiwan with LA or mUC that did not progress after completion of 1L platinum-containing chemotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
